

RELIATech GmbH
Lindenerstr. 15
38300 Wolfenbüttel
Germany

Tel.: +49 5331 8586 987
Fax.: +49 5331 8586 989
Email: info@reliatech.de
web: www.reliatech.de

Antagonistic Antibody of Human VEGFR-2 (#6B11)

Description: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified human VEGFR2 N-terminal fragment (AA N30-200)). IgG₁ fraction of the tissue culture supernatant was purified by Protein G affinity chromatography.

Host species	Mouse
Antigen:	hVEGFR-2 N-terminal fragment (N30-200)
Purification:	Protein G affinity chromatography
Stabilizer:	none
Formulation:	lyophilized

Formulation: Lyophilized from a 0.2 µm filtered solution in phosphate-buffered saline (PBS)

Reconstitution: Reconstitute with sterile PBS.


Storage: Lyophilized samples are stable when stored at -70°C. Reconstituted antibody can also be aliquotted and stored frozen at -70°C at least for six months without detectable loss of activity. **Avoid repeated freeze-thaw cycles.**

Specificity: This antibody recognizes hVEGFR-2 in western blot and it shows no cross-reactivity with hVEGFR-1.

Applications

- 1. Attenuation of VEGF-induced VEGFR2 tyrosine phosphorylation:** This antibody attenuates VEGF-induced VEGFR2 tyrosine phosphorylation.
- 2. Western blot:** Yes.
- 3. Other applications:** not tested

Optimal dilutions should be determined by each laboratory for each application.



HUVECs were pre-treated with 5.0, 25µg/ml mV1001.1m-h for 30 min and then stimulated with rhVEGF (10ng/ml) for 30min. The phospho-VEGFR2 was detected by detected with IP-Western for P-Tyrosine

Usage: Anti-human VEGFR-2/KDR is offered for research use. Not for drug use. **Not for human use!**

Catalogue number: mV1001.1m-h **Size:** 200 µg

Lit.: Ptaszynska et al., Mol Cancer Res. 2008, 6(3):352-63.